SEC Company Response from NOVARTIS AG (NVS, NVSEF) (CIK 0001114448) (NVS) — Apr 25, 2012
NOVARTIS AG (NVS, NVSEF) (CIK 0001114448)
Date: April 25, 2012 · CIK: 0001114448 · Accession: 0001104659-12-028169
AI Filing Summary & Sentiment
File numbers found in text: 001-15024
Letter
Novartis AG Form 20-F for Fiscal Year Ended December 31, 2011 Filed January 25, 2012 File No. 001-15024
Re:
Dear Mr. Rosenberg:
We are in receipt of your letter addressed to Jonathan Symonds, our Chief Financial Officer, dated April 12, 2012. As agreed in an April 17, 2012 telephone call between Barry Rosenfeld, of our affiliate Novartis Corporation, and Lisa Vanjoske, Assistant Chief Accountant at SEC, our time to respond to your letter is extended through and including May 10, 2012.
Respectfully submitted,
Novartis AG
Show Raw Text
CORRESP
1
filename1.htm
Novartis AG
Postfach
4002 Base
Switzerland
April 25, 2012
Mr. Jim B. Rosenberg
Senior Assistant Chief Accountant
US Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
Re:
Novartis AG
Form 20-F for Fiscal Year Ended December 31, 2011
Filed January 25, 2012
File No. 001-15024
Dear Mr. Rosenberg:
We are in receipt of your letter addressed to Jonathan Symonds, our Chief Financial Officer, dated April 12, 2012. As agreed in an April 17, 2012 telephone call between Barry Rosenfeld, of our affiliate Novartis Corporation, and Lisa Vanjoske, Assistant Chief Accountant at SEC, our time to respond to your letter is extended through and including May 10, 2012.
Respectfully submitted,
Novartis AG
/s/ JONATHAN SYMONDS
/s/ FELIX R. EHRAT
Jonathan Symonds
Felix R. Ehrat
Chief Financial Officer
General Counsel
Novartis Group
Novartis Group